FUNDACIÓN RAMÓN ARECES

Simposio Internacional
Vitamina D y cáncer: promesa o realidad

International Symposium
Vitamin D and cancer: promise or reality

Madrid, 28 y 29 de marzo de 2011
Madrid, March 28-29 , 2011

CURRÍCULUM VÍTAE / *CV*

1. Luciano Adorini
2. Ana Aranda
3. Roger Bouillon
4. Moray Campbell
5. Carsten Carlberg
6. David Feldman
7. Edward Giovanucci
8. Michael Holick
9. Candace Johnson
10. María Jesús Larriba
11. Alberto Muñoz
12. Héctor G. Pálmer
13. Román Pérez-Fernández
14. Jörg Reichrath
15. Donald L Trump
16. JoEllen Welsh

Luciano Adorini

After graduating in Medicine at the University of Padova, Dr. Adorini has performed post-doctoral studies at the University of California, Los Angeles and Massachusetts Institute of Technology. He is currently Chief Scientific Officer at Intercept Pharmaceuticals, and has previously worked at Sandoz, Roche, and BioXell. Dr. Adorini has studied several aspects of antigen recognition by T cells and has analyzed immunoregulatory mechanisms to develop immunosuppressive strategies applicable to the treatment of inflammatory and autoimmune diseases. He has made significant contributions in the field of antigen presentation, peptide-MHC interactions and in the use of synthetic peptides to selectively modulate immune responses. He has extensively studied VDR-mediated immunoregulation, describing the effects of VDR agonists on dendritic cells and regulatory T cells. His current interests are focused on the role of bile acid receptors FXR and TGR5 in immunoregulation, and on the pathogenesis and treatment of autoimmune diseases. His preclinical research work has been clinically translated in a number of different indications. He is author of over 270 scientific publications and is a highly cited researcher in Immunology.

VOLVER / TO RETURN ↑

Ana Aranda

Ana Aranda is a Research Professor of the Spanish Research Council at the Instituto de Investigaciones Biomédicas of Madrid. She got her Ph.D in Biology at the Universidad Complutense of Madrid, and after a post-doctoral period at New York University Medical Center, she established her own research group at the Instituto de Investigaciones Biomédicas, where she was Director from 1991 to 1997. She is now the Institutional Coordinator of the Spanish Research Council in Madrid. She has carried out her research in the field of Molecular Endocrinology. Her laboratory is presently involved in studies of the mechanisms of transcriptional regulation of gene expresssion by different nuclear receptors.and in the role of these transcription factors in cell proliferation, transformation and cancer. She has been awarded with several scientific prices including the prices Pharmacia & Upjhon in Neuroendocrinology (2000), SERONO 2000 of the Spanish Society of Endocrinology and Nutrition (2000), Fundación de Ciencias de la Salud (2001) and the Lilly Medal of the Spanish Society of Endocrinology and Nutrition (2006).

VOLVER / TO RETURN ↑

Roger Bouillon

Roger Bouillon is professor (emeritus since 2010) in endocrinology (internal medicine) at the University and University Hospital of the Catholic University of Leuven (K.U.Leuven) in Belgium. Hormonal regulation of bone metabolism and vitamin D remained the primary focus of his research although the laboratory of endocrinology and endocrine clinic is also involved in many other endocrine diseases.
He is a member of the Science Advisory Board of the Flemish Government (president of Science policy commission). He is a member of the Royal Academy of Medicine (Belgium) and a Fellow of the Royal College of Physician (London). He was a founding member and later President of the European Board of Endocrinology (UEMS 1988-2002). He is a member of several European Science Foundation Committees (Board member of the European Medical Research Council) and of the European Space Agency Life Science working group. He is now president of the International Bone and Mineral Society (IBMS) and co-organizer of the vitamin D workshop.
He is coauthor of more than 400 peer reviewed articles that generated about 20,000 ISI citations. The main topics of his research deal with various aspects of bone and calcium and bone homeostasis and this spans the spectrum of basic, translational and clinical research. Vitamin D is a major research focus throughout his scientific career.

VOLVER / TO RETURN ↑

Moray Campbell

Moray Campbell (UK, 1966) is an Associate Professor of Oncology, at the Roswell Park Cancer Inst, Buffalo, USA. He received his Ph.D. in Microbiology at the University of Kent in 1994. Subsequently he undertook post-doctoral work at UCLA, Los Angeles, USA and the University of Birmingham, UK. Dr. Campbell's work has been in the field of nuclear receptors and in particular focusing on the epigentic mechanisms that govern their ability to control gene and miRNA regulation. He has focused on prostate cancer to define the mechanism of action of the VDR, and related nuclear receptors, to establish how co-repressors selectively limit the key growth regulatory mechanisms of action. He has an established record of translating and coordinating these research experiences into the education arena and has been instrumental in establishing several international graduate training consortiums, in which he holds senior management positions. He has received several scientific awards, from the Vitamin D Workshop, (1997) and the British Association for Cancer Research (2000).

VOLVER / TO RETURN ↑

Carsten Carlberg

Carsten Carlberg (Germany, 1963) is professor for Computational Biology at the University of Luxembourg and Professor for Biochemistry at the University of Eastern Finland in Kuopio. He received his PhD in Biochemistry from the Free University Berlin. Moreover, he worked at the Central Research Units of Hoffmann-La Roche in Basel, at the Geneva University Hospital and the University of Düsseldorf. Since more than 20 years Prof. Carlberg works with a number of different nuclear receptors, but his main model is the vitamin D receptor (VDR). During the last year the focus of the Carlberg team shifted to the genome- and transcriptome-wide analysis of of the location and action of nuclear receptors (RAR, LXR and PPAR)and other transcription factors (e.g. Nrf2, TCF7L2, MYC). From 2006-2009 Prof. Carlberg was the co-ordinator of the EU-funded Marie Curie Research Training Network NucSys (Systems biology of nuclear receptors).

VOLVER / TO RETURN ↑

David Feldman

David Feldman (USA 1939) M.D. is Emeritus Professor of Medicine (Active) at Stanford University School of Medicine, Stanford, CA, USA. Dr. Feldman was chief of the Stanford Endocrinology Division for 10 years and he has been director of the Endocrinology, Diabetes and Aging Training Grant for 15 years. Dr. Feldman's current research focus is vitamin D and hormone dependent cancer including prostate cancer and breast cancer. His laboratory investigates the role of steroid hormone receptors, particularly the vitamin D receptor, in the mechanism of action of vitamin D inhibition of breast and prostate cancer growth. He is actively involved in clinical trials studying the use of vitamin D in the therapy of prostate and breast cancer. Dr. Feldman is a member of several prestigious scientific societies and was recently honored with an award for a career of outstanding contributions to vitamin D research by the Vitamin D Workshop. He reviews for and has served on the editorial boards of multiple medical and scientific journals, and has been a member of many national grant review panels. Dr. Feldman has authored over 250 medical research articles, reviews, editorials, and book chapters. He is the editor-in-chief of "Vitamin D", now in preparation for its third edition and is an editor of the first, second and third editions of "Osteoporosis". Both books are considered the major texts in their field.

VOLVER / TO RETURN ↑

Edward Giovanucci

Dr. Giovannucci is a Professor in the Departments of Nutrition and Epidemiology at the Harvard School of Public Health. He received a medical degree from the University of Pittsburgh School of Medicine in 1984, and did his residency in anatomic pathology at the University of Connecticut. He received a doctoral degree in epidemiology from the Harvard School of Public Health in 1992. His research focuses on how nutritional, environmental and lifestyle factors relate to various malignancies, especially those of the prostate and colorectum. A specific area of interest is in the etiologic mechanisms underlying the relation between these modifiable factors and cancer risk. His work has included the study of how nutrition and other lifestyle factors impact on cancer risk by influencing levels of insulin, insulin-like growth factors, vitamin D metabolites, and steroid hormones. Another area of interest is how nutrients may interact with genetic susceptibilities in determining an individual's risk. Recent publications include investigations of the role of vitamin D levels in myocardial infarction and in the survival of patients with colorectal cancer.

VOLVER / TO RETURN ↑

Michael Holick

Michael F. Holick, Ph.D., M.D. is Professor of Medicine, Physiology and Biophysics; Director of the General Clinical Research Unit; and Director of the Bone Health Care Clinic and the Director of the Heliotherapy, Light, and Skin Research Center at Boston University Medical Center.
After earning a Ph.D. degree in biochemistry, a medical degree, and completing a research postdoctoral fellowship at the University of Wisconsin, Madison, Dr. Holick completed a residency in medicine at the Massachusetts General Hospital in Boston.
Dr. Holick has made numerous contributions to the field of the biochemistry, physiology, metabolism, and photobiology of vitamin D for human nutrition. As a graduate student he was the first to identify the major circulating form of vitamin D in human blood as 25-hydroxyvitamin D3. He then isolated and identified the active form of vitamin D as 1,25-dihydroxyvitamin D3. He participated in the first 21 step chemical synthesis of 1,25-dihydroxyvitamin D3 that was used in the first clinical trials to treat renal osteodystrophy and inborn and acquired disorders in vitamin D metabolism including pseudovitamin D deficiency rickets. He determined the mechanism for how vitamin D is synthesized in the skin, demonstrated the effects of aging, obesity, latitude, seasonal change, sunscreen use, skin pigmentation, and clothing on this vital cutaneous process. Dr. Holick has established global

recommendations advising sunlight exposure as an integral source of vitamin D. He has helped increase awareness in the pediatric and medical communities regarding vitamin D deficiency pandemic, and its role in causing not only metabolic bone disease, and osteoporosis in adults, but increasing risk of children and adults developing common deadly cancers, schizophrenia, infectious diseases including TB and influenza, autoimmune diseases including type 1 diabetes and multiple sclerosis, type 2 diabetes, stroke and heart disease. He also observed the pregnant women who were vitamin D deficient were at increased risk for preeclampsia and requiring a C-section. Dr. Holick pioneered a novel treatment for psoriasis through translational research demonstrating that the active form of vitamin D could be used for the treatment of this hyperproliferative skin disorder. This treatment is considered to be the first line treatment for most patients with mild psoriasis.

Dr. Holick is a Diplomate of the American Board of Internal Medicine, a Fellow of the American College of Nutrition, and a member of the American Academy of Dermatology and the American Association of Physicians. He is the recipient of numerous awards and honors, including the American Skin Association's Psoriasis Research Achievement Award, the American College of Nutrition award, the Robert H. Herman Memorial Award in Clinical Nutrition from the American Society for Clinical Nutrition, the Annual General Clinical Research Centers' Program Award for Excellence in Clinical Research, the Linus Pauling Functional Medicine Award from the Institute for Functional Medicine, the Linus Pauling Prize for Human Nutrition, the DSM Innovation Award and most recently, the AACC Outstanding Speaker Award for 2009. Dr. Holick serves on a number national committees and editorial boards and has organized and/or co-chaired several international symposia. He has authored more than 300 peer-reviewed publications, and written more than 200 review articles, as well as numerous book chapters. He has acted as editor and/or co-editor on 12 books, and has written *The UV Advantage in 2004* and *The Vitamin D Solution* in 2010.

VOLVER / TO RETURN ↑

Candace Johnson

I am the Deputy Director of Roswell Park Cancer Institute, Chair of the Department of Pharmacology & Therapeutics. My research interests include translational research to facilitate the efficient application of promising laboratory findings in clinical studies; preclinical design and development of more effective therapeutic approaches to cancer using highly characterized tumor models; and mechanisms of vitamin D mediated antiproliferative effects either alone or in combination with

other cytotoxic agents. I received my PhD in Immunology from the Ohio State University in 1977. After three years of post-doctoral training at the Michigan Cancer Foundation in Detroit, I joined the AMC Cancer Research Center in Denver as a Staff Scientist. During the next eight years, I was appointed Laboratory Chief of Experimental Hematology, Assistant Professor of Medicine at the University of Colorado and Full Member of the Comprehensive Cancer Center in Denver. In 1989, I was recruited to the University of Pittsburgh and the University of Pittsburgh Cancer Institute (UPCI) where I was Professor in the Departments of Pharmacology and Medicine, the Deputy Director of Basic Science at the UPCI and the Co-Program Leader of the Molecular Therapeutics/Drug Discovery Program in the cancer center. I have maintained continuous independent peer-reviewed funding from 1979 when I was awarded an NIH postdoctoral fellowship from the NCI, and have significant RO1 funding. The studies proposed in your grant match well my research interests and expertise.

Professional Experience

1979 - 1981 Senior Research Associate, Michigan Cancer Foundation, Detroit, MI
1981 - 1985 Scientist, AMC Cancer Research Center, Denver, CO
1985 - 1988 Senior Scientist, AMC Cancer Research Center
1988 - 1989 Adjunct Asst Professor, Dept of Medicine, Univ. of Colorado School of Medicine, Denver, CO
1988 - 1989 Chief, Laboratory of Experimental Hematology, AMC Cancer Research Center
1989 - 1993 Associate Professor, Dept of Pathology, Univ. of Pittsburgh School of Medicine, Pittsburgh, PA
1989 - 1994 Associate Professor, Dept of Otolaryngology, Univ. of Pittsburgh School of Medicine (tenure conferred 1992)
1993 - 1994 Associate Professor, Dept of Pharmacology, Univ. of Pittsburgh School of Medicine
1995 - 1997 Professor, Depts of Otolaryngology and Pharmacology, Univ. of Pittsburgh School of Medicine
1997 - 2002 Professor, Depts of Pharmacology and Medicine, Univ. of Pittsburgh School of Medicine
2002 - 2008 Senior Vice-President/Associate Director, Translational Research, Roswell Park Cancer Institute, Buffalo, NY
2002 - Professor of Oncology, Dept of Pharmacology and Therapeutics, Roswell Park Cancer Institute
2002 - Professor, Depts of Pharmaceutical Sciences and Urology, University at Buffalo, NY
2005 - Robert, Lew and Ann Wallace Endowed Chair for Translational Research
2007 - Chair, Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute
2008 - Deputy Director, Roswell Park Cancer Institute

Other Experience and Professional Memberships

1987 - 1989 Full Member, University of Colorado Comprehensive Cancer Center
1989 - 2002 Full Member, Pittsburgh Cancer Institute, National Cancer Institute Designated Cancer Center
1990 - 1994 Member, Experimental Therapeutics-2 Study Section, Division of Research Grants, NIH
1990 - 2002 Co-Program Director, Molecular Therapeutics/ Drug Discovery Program, University of Pittsburgh Cancer Institute, NCI designated Cancer Center
1994 - Member, NIH Reviewers Reserve
1995 - 2000 Member, Experimental Therapeutics-2 Study Section, Division of Research Grants, NIH
1998 - 2002 Deputy Director for Basic Research, University of Pittsburgh Cancer Institute, NCI designated Cancer Center
2000 - 2004 Member, NCI Initial Review Group, Subcommittee A – Cancer Centers (Parent Committee) NIH
2003 - 2005 Chair, Scientific Advisory Committee, Ralph Wilson Medical Research Foundation

VOLVER / TO RETURN ↑

María Jesús Larriba

María Jesús Larriba (Spain, 1978) is Postdoctoral Researcher at the Instituto de Investigaciones Biomédicas (Spanish Research Council) in Madrid. She obtained her degree in Biochemistry in 2001 at the Autonomous University of Madrid and her Ph.D. in Biochemistry, Molecular Biology and Biomedicine in 2006 at the same University. Her work has been focused on the antitumoral effects of vitamin D in colon cancer and on the mechanisms of resistance to vitamin D in this neoplasia. She has proposed the over expression of the transcription factors Snail1 and Snail2 as a major mechanism
responsible for the repression of vitamin D receptor expression and responsiveness in colon cancer.
Dr. Larriba has received Awards such as the Autonomous University of Madrid Thesis (2005-2006), the Vitamin D Workshop Young Investigator (2003, 2009) and the Spanish Cancer Network Young Investigators Meeting (2010).

VOLVER / TO RETURN ↑

Alberto Muñoz

Alberto Muñoz (Spain, 1958) is Research Professor at the Instituto de Investigaciones Biomédicas, Spanish Research Council, in Madrid. He received his Ph.D. in Sciences at the Autonomous University of Madrid in 1983. He worked at the Center for Molecular Biology (Madrid), Antibióticos S.A. (Madrid), European Molecular Biology Laboratory (Heidelberg) and Institut für Molekulare Pathologie (Vienna). Prof. Muñoz' work has been in the field of nuclear hormone receptors since his contribution to the characterization of the *erbA* oncogene product as the thyroid hormone receptor in 1986. He has conducted studies on the gene regulatory effects of thyroid hormone in the brain and the mammary gland, and on the mechanism of action of the glucocorticoid receptor. Since 2000, his laboratory is focused on the action of vitamin D and its receptor in human colon and breast cancer cells. He has also held management positions, as Coordinator of Molecular and Cellular Biology at the National Agency for Scientific Evaluation (1997-2000) and Ministerio de Educación y Ciencia (2001-2006), and has received several scientific Awards such as the Rey Jaime I for Basic Research (1993), Francisco Cobos Foundation for Biomedical Research (2000), Harington-De Visscher Award of the European Thyroid Association (1999) and Vilardell Foundation (2006).

VOLVER / TO RETURN ↑

Héctor G. Pálmer

Héctor G. Pálmer obtained his PhD in Biochemistry and Molecular Biology in 2001 from the Universidad Autónoma de Madrid. At that time, he developed different projects studying the Wnt/b-catenin and Vitamin D crosstalk and the anti-tumoral capacity of vitamin D analogues on human colon cancer.
In 2003 Héctor G. Palmer was awarded with the Marie Curie Intra European Fellowship and in 2004 joined the London Research Institute-Cancer Research UK (LRI-CRUK) as Postdoctoral fellow under the leadership of Prof. Fiona M. Watt. As Postdoctoral Fellow, he described VDR as a novel transcriptional effector of the Wnt pathway that controls stem cells fate in adult epidermis. He also discovered that the central role of the Wnt signalling in tumor initiation depends on VDR function, opening a new opportunity for the use of Vitamin D based drugs to prevent cancer development.
In 2008 Héctor returned as Principal Investigator at the Institut d'Investigació Oncològica de Vall-Hebron (VHIO) in Barcelona, where he continues his work on the role of Wnt pathway driving normal and cancer stem cell fate in colon cancer and its relevance in tumor initiation, progression and metastasis.

VOLVER / TO RETURN ↑

Román Pérez-Fernández

Román Pérez-Fernández is Professor of Physiology at the University of Santiago de Compostela, Spain. He finished Medical School in 1982, and received his Ph.D. in 1986 at University of Santiago de Compostela. He has worked at the Istituto Portugues de Oncologia (Lisbon, Portugal), Instituto di Clinica Ostetrica e Ginecologica de la Universitá di Modena (Modena, Italy), and the Sloan-Kettering Institute for Cancer Research (New York, USA). Over the last 15 years, he has been carrying out research on the role of transcriptional factors in cancer development, focusing specifically on the Pit-1 transcription factor and the vitamin D receptor in breast carcinogenesis. He is a member of several scientific societies (European Association for Cancer Research, The Endocrine Society, ASEICA), and has published 40 peer-review papers in international journals.

VOLVER / TO RETURN ↑

Jörg Reichrath

JÖRG REICHRATH is Professor for Dermatology and Deputy Director of the Clinic for Dermatology, Allergology and Venerology at the Saarland University Hospital in Homburg/Saar, Germany. Main research interests include the cutaneous vitamin D endocrine system (VDES), photobiology, dermato-endocrinology and dermato-oncology. He is a member of numerous national and international scientific organisations, including the German Dermatological Society (DDG), the Deutsche Krebsgesellschaft (DKG), the Arbeitsgemeinschaft Dermatologische Forschung (ADF) of the DDG, and the German Dermatologic Co-operative Oncology Group (DeCOG). He has been awarded numerous prices including the Arnold-Rikli-price 2006. Jörg Reichrath received his academic degrees (Dr. med., venia legendi) from the Saarland University, Germany.

VOLVER / TO RETURN ↑

Donald L Trump

Dr. Donald Trump is President and CEO of the Roswell Park Cancer Institute. Dr. Trump's clinical and research program has focused on the development of new approaches in the treatment of genitourinary cancer, especially prostate cancer. For the past 15 years Dr. Trump and his colleague, Dr. Candace Johnson, Deputy Director of the Roswell Park Cancer Institute have focused their research efforts on the evaluation of the biologic and clinical role of vitamin D and vitamin D analogues in cancer etiology and therapeutics.

Dr. Trump has been a leader in comprehensive cancer centers for more than 2 decades. He served as Director, Experimental Therapeutics, Duke Comprehensive Cancer Center, Deputy Director for Clinical Investigators in the University of Pittsburgh Comprehensive Cancer Center. Prior to being appointed President and CEO of Roswell Park Cancer Institute Dr. Trump was co-PI of the Roswell Park CCSG grant, Associate Institute Director and SVP for Clinical Investigation. Dr. Trump serves on the external advisory boards of several comprehensive centers and has been a NCI reviewer of CCSG grants. Dr. Trump has been co-PI or PI on numerous peer-reviewed NIH, DOD and ACS grants and continues his active translational research program. Dr. Trump is recognized for his research in vitamin D insufficiency and deficiency in cancer patients, especially prostate cancer patients.

VOLVER / TO RETURN ↑

JoEllen Welsh

JoEllen Welsh is an Empire Innovations Professor at the University at Albany Cancer Research Center in Rensselaer, NY, USA. She also holds an appointment as Professor in the Department of Environmental Health Sciences of the School of Public Health, University at Albany. She received her BA in Biology from Rutgers University, New Brunswick, NJ and her Ph.D. in Nutritional Biochemistry from Cornell University, Ithaca, NY. Prior to joining the University at Albany, Dr. Welsh taught and conducted research at Mount St Vincent University (Halifax, NS, Canada), the University of Ottawa (Ottawa, Ontario, Canada), the W. Alton Jones Cell Science Center (Lake Placid, NY, USA) and the University of Notre Dame (Notre Dame, IN, USA). Since 1985, Dr. Welsh has focused her research on vitamin D and chronic disease, using cellular and whole animal approaches. Her lab was the first to report the induction of apoptosis by vitamin D compounds, and

to develop and characterize vitamin D resistant breast cancer cell lines. Recent emphasis has been on novel roles of vitamin D in tumor cell metabolism, adipogenesis and innate immunity in mammary gland. Dr. Welsh has mentored 11 Doctoral and 3 Masters students and supervised 8 post-doctoral fellows. She has been a long term member of grant review panels for NIH [Chemo/Dietary Prevention] and the American Institute for Cancer Research and active participant in the Vitamin D Workshops. Since 1985, Dr. Welsh's research on vitamin D has been externally funded from the Canadian National Science & Engineering Research Council, the Canadian Medical Research Council, the Juvenile Diabetes Foundation, the Kidney Foundation, the American Institute for Cancer Research, the Susan G. Komen Foundation, the DOD Breast Cancer Research Program and the NIH National Cancer Institute.

VOLVER / TO RETURN ↑